{"filing":{"accession_number":"0001840706-26-000214","cik":"0001840706","ticker":"SOPH","company_name":"SOPHiA GENETICS SA","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"a2026agmresultssophiagenet.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840706/000184070626000214/a2026agmresultssophiagenet.htm"},"events":[{"id":12612,"run_id":11187,"accession_number":"0001840706-26-000214","anchor_item_number":"EX-99.1","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.95,"summary":"SOPHiA GENETICS SA amended its Articles of Association, a foundational governance document establishing the company's corporate structure, share capital framework, shareholder rights, and board powers. The amendments appear to be routine administrative provisions governing capital ranges, share restrictions, and meeting procedures.","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9513,"accession_number":"0001840706-26-000214","item_number":"EX-99.1","item_title":"amendedarticlesofassocia.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.95,"reasoning":"This exhibit is the amended Articles of Association of SOPHiA GENETICS SA, a foundational governance document that establishes the company's corporate structure, share capital framework, shareholder rights, and board powers. While governance-related, it is a routine administrative disclosure of bylaws rather than a discrete material event (such as an executive departure, M\u0026A activity, or financial restatement) that would affect investor assessment. The amendments appear to be standard provisions governing capital ranges, share restrictions, and meeting procedures.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:07:15.909083+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":12613,"run_id":11187,"accession_number":"0001840706-26-000214","anchor_item_number":"EX-99.2","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"SOPHiA GENETICS held its 2026 Annual General Meeting of shareholders, approving all proposals including the election of Dr. Jurgi Camblong as Executive Chairman (99.79% approval) and Ross Muken as a new Board member and incoming CEO effective July 1, 2026 (99.88% approval), reflecting a significant leadership transition and governance restructuring.","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":[{"id":9514,"accession_number":"0001840706-26-000214","item_number":"EX-99.2","item_title":"post-agmpr_prnewswire.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing the results of SOPHiA GENETICS' 2026 Annual General Meeting of shareholders. The primary disclosure is the approval of all shareholder proposals, including the election of Dr. Jurgi Camblong as Executive Chairman (99.79% approval) and Ross Muken as a new Board member and incoming CEO effective July 1, 2026 (99.88% approval). While the announcement also contains elements of executive appointment and governance changes, the core event is the shareholder vote results themselves, which is material to investors as it reflects a significant leadership transition and governance restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:07:15.909083+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9513,"accession_number":"0001840706-26-000214","item_number":"EX-99.1","item_title":"amendedarticlesofassocia.htm","event_type":"governance_other","event_domain":"governance","is_material":false,"confidence":0.95,"reasoning":"This exhibit is the amended Articles of Association of SOPHiA GENETICS SA, a foundational governance document that establishes the company's corporate structure, share capital framework, shareholder rights, and board powers. While governance-related, it is a routine administrative disclosure of bylaws rather than a discrete material event (such as an executive departure, M\u0026A activity, or financial restatement) that would affect investor assessment. The amendments appear to be standard provisions governing capital ranges, share restrictions, and meeting procedures.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:07:15.909083+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22"},{"id":9514,"accession_number":"0001840706-26-000214","item_number":"EX-99.2","item_title":"post-agmpr_prnewswire.htm","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"This exhibit is a press release announcing the results of SOPHiA GENETICS' 2026 Annual General Meeting of shareholders. The primary disclosure is the approval of all shareholder proposals, including the election of Dr. Jurgi Camblong as Executive Chairman (99.79% approval) and Ross Muken as a new Board member and incoming CEO effective July 1, 2026 (99.88% approval). While the announcement also contains elements of executive appointment and governance changes, the core event is the shareholder vote results themselves, which is material to investors as it reflects a significant leadership transition and governance restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T12:07:15.909083+00:00","company_name":"SOPHiA GENETICS SA","ticker":"SOPH","filing_date":"2026-06-22"}]}